This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barbaro, D, G Boni, G Meucci, U Simi, P Lapi, P Orsini, C Pasquini, F Piazza, M Caciagli, and G Mariani. 2003. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110–4115.
Golger, A, TR Fridman, S Eski, IJ Witterick, JL Freeman, and PG Walfish. 2003. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest 26:1023–1031.
Haugen, BR, F Pacini, C Reiners, M Schlumberger, PW Ladenson, SI Sherman, DS Cooper, KE Graham, LE Braverman, MC Skarulis, TF Davies, LJ DeGroot, EL Mazzaferri, GH Daniels, DS Ross, M Luster, MH Samuels, DV Becker, HR Maxon III, RR Cavalieri, CA Spencer, K McEllin, BD Weintraub, and EC Ridgway. 1999. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877–3885.
Ladenson, PW, LE Braverman, EL Mazzaferri, F Brucker-Davis, DS Cooper, JR Garber, FE Wondisford, TF Davies, LJ DeGroot, GH Daniels, DS Ross, and BD Weintraub. 1997. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888–896.
Ladenson, PW, F Pacini, M Schlumberger, et al. 2004. Randomized study of remnant ablation using recombinant human TSH versus thyroid hormone withdrawal. The Endocrine Society Abstract S35-1, New Orleans, 16–19 June.
Mazzaferri, EL, and RT Kloos. 2005. Carcinoma of follicular epithelium: radioiodine and other treatment outcomes. In: Werner’s & Ingbar’s The Thyroid: A Fundamental and Clinical Text, 9th edn. Philadelphia: Lippincott Willams & Wilkins (Braverman LE, Utiger RD, eds) 934–966.
Pacini, F, E Molinaro, MG Castagna, F Lippi, C Ceccarelli, L Agate, R Elisei, and A Pinchera. 2002. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063–4068.
Robbins, RJ, and AK Robbins. 2003. Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 88(5):1933–1938.
Robbins, RJ, RM Tuttle, RN Sharaf, SM Larson, HK Robbins, RA Ghossein, A Smith, and WD Drucker. 2001. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619–625.
Schlumberger, M, M Ricard, and F Pacini. 2000. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 143:557–563.
Serhal, DI, MP Nasrallah, and BM Arafah. 2004. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab 89:3285–3289.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Amdur, R.J., Mazzaferri, E.L. (2005). Using rhTSH Prior to I-131 Therapy. In: Amdur, R.J., Mazzaferri, E.L. (eds) Essentials of Thyroid Cancer Management. Springer, Boston, MA. https://doi.org/10.1007/0-387-25714-4_31
Download citation
DOI: https://doi.org/10.1007/0-387-25714-4_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25713-6
Online ISBN: 978-0-387-25714-3
eBook Packages: MedicineMedicine (R0)